Literature DB >> 6168241

Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (BD 40A).

K Tomioka, T Yamada, H Ida.   

Abstract

The effects of formoterol (BD 40A) on the rat and guinea-pig hypersensitivity reactions and on mouse IgE antibody formation was investigated. The inhibitory effect of intravenously (i.v.) and perorally (p.o.) administered formoterol on (mouse) IgE-mediated 24-hr passive cutaneous anaphylaxis (PCA) in rats was 6.3 and 33 times, respectively, more potent than that of salbutamol. This action was antagonized by pretreatment with propranolol. Formoterol at the dose exhibiting considerable PCA inhibition had no effect on histamine- and 5-hydroxytryptamine-induced skin reactions. Formoterol, administered i.v. or p.o., inhibited (guinea-pig) IgE-mediated 8-day PCA in guinea-pigs. In the isolated guinea-pig lung, both formoterol and salbutamol exhibited dose-dependent inhibition of antigen-induced histamine release. However, in the isolated rat mesenterium these two drugs showed only partial inhibition of antigen-induced mast cell degranulation, whereas disodium cromoglycate (DSCG) manifested dose-dependent inhibition. Neither formoterol nor salbutamol affected the hapten-specific IgE antibody response in female BDF1 mice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168241

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.

Authors:  T Yamada; M Saito; T Mase; H Hara; H Nagaoka; K Murase; K Tomioka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 2.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  D Faulds; L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 3.  Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms.

Authors:  Gary P Anderson
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

4.  Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma.

Authors:  A B Becker; F E Simons
Journal:  Lung       Date:  1990       Impact factor: 2.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.